Today, Monday, 02012.03.19, Illumia issued the following press release: Illumina Files Definitive Proxy Materials and Sends Letter to Stockholders
The press release contained the following in bold, so I've bold it.
In short, this market is at a breakthrough point and it’s an exciting time to be an Illumina stockholder: genetic sequencing is the future of healthcare, and Illumina is at the forefront of this transformation.
I liked some of the following blurb.
"Roche’s blatantly opportunistic hostile offer of $44.50 per share for Illumina [...] was unanimously rejected [by the Board] as grossly inadequate."
I agree! $44.50 is blatantly opportunistic and grossly inadequate.
The Illumina press release also contained the following. (I preserved the bolding.)
"The Board rejected Roche’s offer because it dramatically undervalues Illumina, because it was timed to take advantage of what we believe was a temporary price dip caused by external events, and because it falls far short of the value we believe we can deliver to our stockholders by pursuing our strategic plan."
No comments:
Post a Comment